Opinion: Editing Babies’ Genes and the Pitfalls of Life Sciences Publicity
Life science research is often fascinating and full of promise. It's also a potential minefield for the marketing professionals tasked with publicizing breakthroughs in life science fields from environmental protection to human genetics.
Just how dangerous such publicity can be was evident after the recent announcement that a Chinese biomedical researcher had for the first time performed genetic editing on an unborn baby.
Scientists, ethicists and government leaders around the world were stunned when researcher Dr. He Jiankui of the Southern University of Science and Technology in Shenzhen claimed he had successfully altered the genes of twin girls in a way that protected them from HIV, the virus that causes AIDS.
The announcement was, in fact, the trigger for a public relations disaster. What followed was a global controversy over the kind of marketing hype that life science researchers and companies should avoid at all costs.
Overall, marketing and public relations campaigns seem poorly suited for life sciences activities, especially those involving human health. This kind of medical research inspires awe and should be treated with life-or-death seriousness.
Unfortunately, whether out of ignorance or shortsightedness, Dr. He and his team apparently forgot the seriousness of their breakthrough announcement and its impact on global public opinion. They may have overlooked the fact that altering human genes in the unborn could trigger a collective sense of anger, as well as condemnation and denunciation, among the public as well as within the scientific and medical communities.
Some media reports say the incident may have a negative impact on the entire Chinese biomedical community's international reputation.
Dr. He's gene-edited baby announcement was officially reported in China on Nov. 26 by the People's Daily media website under the headline "World's First Baby Genetically Edited Against AIDS Born in China." The report, which was later withdrawn from the website, was authored by the general manager of the business unit of the People's Daily Network in Guangdong province region, and thus could be labeled a soft-sell marketing piece.
It's worth noting that as early as Nov. 25, the U.S. wire service Associated Press released a report about genetically edited babies and Dr. He's research. The report was published by several media outlets including The Washington Post, the biotech news publication STAT, and MIT Technology Review.
Moreover, some four days before the People's Daily report, according to a foreign affairs section article posted on the Beijing News media platform, Dr. He co-authored with five other experts a paper that was published by the genetic editing peer-reviewed publication The CRISPR Journal. Another co-author was Ryan Ferrell, an American, who has been described as a public relations expert tied to genetically edited baby experiments.
On Nov. 28, at the Second International Summit of Human Genome Editing held in Hong Kong, Dr. He claimed he was surprised that the general media had announced his findings before the news was released to the scientific community. But his comments clashed with the fact that the Associated Press report on Nov. 25 was partly based on an October interview with Dr. He that a reporter conducted in a Shenzhen laboratory.
The wire report said the gene editing of a baby would represent a dramatic leap forward for science yet also raise ethical questions. It further noted that Dr. He's claim had not yet been confirmed by an independent third party, nor had his results been published in an academic journal.
For some researchers in the fast-moving and attention-grabbing life sciences arena, it's tempting to seek and even indulge in the media spotlight. A breakthrough can attract almost overwhelming fame and acclaim.
But the life sciences community — including related companies — should not let the media spotlight distort their professional vision. Discoveries and breakthrough claims must be managed prudently and with proper respect not only for science but for life itself. In this vital field, marketing ploys and exaggerations have no place.
A mature life sciences company applies professional standards to every public relations activity. Such a company has strict rules for compliance, and requires that press releases are reviewed by professionals in as many relevant departments as necessary before anything is shared with the media. Indeed, legal compliance and clinical experts must confirm the veracity of every word, every comma, before the news is made public.
Moreover, life science practitioners including researchers must be well-versed in applicable laws and regulations, medical ethics and professional norms.
In many parts of the world, professional media relations and public affairs experts who work for life sciences companies have earned graduate degrees in science. It's not uncommon to find a spokesperson for a European or an American biomedical company who has earned a master's degree or a doctorate in medicine, biology, organic chemistry or biomedical engineering. Some have even had clinical experience in a medical school.
Chinese public relations practitioners in the life sciences field likewise should have relevant medical background and knowledge. In this area, it seems improvements are needed. Life sciences companies should demand professional expertise, political awareness and high standards for their public relations departments.
Dr. He has tried to blame the news media for the fact that his breakthrough was announced to the world before the scientific community caught wind. But in fact, it seems clear that Dr. He and his public relations team took the initiative by contacting the news media before the gene-edited baby report was published in a scientific journal. The goal appeared to be aimed at generating a major news sensation at home and abroad.
The Chinese social media writers Ye Shui Song and Di Li Hui, whose work appears on the WeChat platform Intelligentsia, sharply rebuked Dr. He for what they said was a move designed to paint him as a "wang hong" — the Chinese expression for internet celebrity — even before the gene editing announcement. Their article entitled "He Jiankui's Publicity Trap Emerges at a Summit Scene" claimed he had repeatedly sought attention after launching a media campaign that packaged him as a gene editing pioneer and scientific genius.
The writers also noted that his paper on what he called a "$100, third-generation gene sequencer" was accepted by a specialty publisher that does not require peer reviews. They also disclosed that many life science field scholars and experts have questioned this and related news reports for their advertising focus — a focus that stands to benefit chest-thumping researchers seeking fame and fortune.
The gene-edited twins breakthrough announcement certainly brought fame to Dr. He. Now, he will likely remain in the media spotlight for some time.
But news of the breakthrough claim failed to bring him much glory. Instead, the announcement was met with various degrees of doubt and disappointment.
Various experts in China and abroad reacted to the announcement by noting that the gene-editing CRISPR technology adopted by Dr. He for human experiments is routinely used by molecular biologists for other applications. It seems Dr. He did not engage any innovative techniques nor provide much of a scientific or technical contribution to advancing the CRISPR technology, they said. Indeed, some argued that babies can be protected from HIV by other means well-known to the medical community.
Dr. He's case is certainly not the first to confront the marketing minefield that surrounds the life sciences field. For example, Theranos, an innovative Silicon Valley company that claimed to have developed a breakthrough blood test found itself in an explosive situation.
The company, Theranos, was headed by young entrepreneur Elizabeth Holmes whose marketing style attracted media and investor attention. Positive write-ups about Holmes and the company appeared in The Wall Street Journal, New Yorker magazine and Fortune magazine. Later, though, regulators accused Theranos of fraud and ordered a halt to the blood tests. The company that was once worth $9 billion eventually collapsed.
Another minefield navigator was a wealthy physician named Dr. Huang Xin Xiang (Patrick Soon-Shiong), who was once called the country's richest Chinese-American. He developed a cancer drug called Abraxane that was approved for treating breast, lung and pancreatic cancer in more than 40 countries.
Dr. Huang, who had a keen mind for business, worked on gene sequencing and founded the biotechnology company NantHealth before listing it on the Nasdaq stock exchange. But in 2017, authorities accused Dr. Huang of fraud and an illegal marketing after his company's stock market listing campaign backfired.
In the run-up to the listing, Dr. Huang had been bombarded with interview requests and questions from reporters from medical publications including STAT. Through social media, NantHealth advertised that it had found new breakthroughs that kill cancer cells, while Dr. Huang claimed he was close to resolving all cancer problems — claims that in turn sparked fierce public debate.
STAT and other media reported that Dr. Huang's promotional video on cancer immunotherapy crossed a red line that was set by U.S. Food and Drug Administration, which limits marketing for drugs under development. The FDA says drugs must be proven safe and effective before they can be marketed.
Today, public and professional reactions to Dr. He's genetic editing announcement have sounded a new alarm for marketing-related efforts in the life sciences sector. Research findings and company publicity in this area must strictly adhere to the principles of medical ethics, as well as relevant laws and regulations. Respect for life and the seriousness of scientific endeavors must be at the heart of any public relations campaign, while marketing hype should be carefully avoided.
Too much confidence can be dangerous. One misstep in the marketing minefield, much like mistakenly ingesting a fake but cleverly advertised drug, can be merciless. Public relations professionals thus have a responsibility to communicate life sciences developments and breakthroughs with transparency, effectiveness and honesty.
Wang Zhen is the managing director at Zhifei Impact Communications.
If you want to submit an opinion piece to Caixin Global, please send an email to firstname.lastname@example.org
May 11 07:05 PM
May 11 06:57 PM
May 11 05:37 PM
May 11 05:33 PM
May 10 06:28 PM
May 10 06:25 PM
May 10 06:08 PM
May 07 08:24 PM
May 07 07:51 PM
May 07 07:39 PM
May 07 04:35 PM
May 06 06:31 PM
May 06 06:25 PM
May 06 06:16 PM
May 05 06:52 PM
- 1Sinopharm’s Vaccine Nears Emergency-Use Approval by WHO
- 2Sinopec to Plow Cash Into Natural Gas as Climate Targets Loom
- 3Li Ka-Shing Unseated by Tesla Battery Supplier as Hong Kong’s Richest Man
- 4Drop in Capital Investment Drags on Caixin New Economy Index
- 5Son-in-Law of Phoenix Media Boss Detained in Peer-to-Peer Lending Probe
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas